Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy.
This study evaluates the effect of treatment with Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy, and the final outcome of pregnancy and fetal status. One hundred and fifty patients received intramuscular injection of Proluton-Depot from 6 weeks to 8 weeks to 16 weeks to 18 weeks gestation. The outcome of this treated group was compared with a similar number of 150 patients with similar problems, but the second group received no hormonal treatment. There was no evidence to suggest that Proluton-Depot had any adverse effect on the infant or the final outcome of pregnancy.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000022:Abortion, Spontaneous / Q000188:drug therapy; D000328:Adult; D003340:Corpus Luteum Maintenance / Q000187:drug effects; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000009:adverse effects* / Q000627:therapeutic use; D007231:Infant, Newborn; D007247:Infertility, Female / Q000188:drug therapy; D010043:Outcome and Process Assessment, Health Care; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects
D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate